Featured Research

from universities, journals, and other organizations

New technology simplifies production of biotech medicines

Date:
May 14, 2014
Source:
VIB
Summary:
The final step in the production of a biotech medicine is finishing with the correct sugar structure. This step is essential for the efficacy of the medicine, but it also makes the production process very complex and expensive. Researchers have developed a technology that shortens the sugar structures whilst retaining the therapeutic efficiency. This technology has the potential to make the production of biotech medicines significantly simpler and cheaper.

Nico Callewaert, who says: "This technology has allowed us to solve an old biotech problem. Since the 1990s, nearly everyone has been working to make the sugar synthesis in biotech production cells as similar to human cells as possible."
Credit: © Bart Van Leuven

The final step in the production of a biotech medicine is finishing with the correct sugar structure. This step is essential for the efficacy of the medicine, but it also makes the production process very complex and expensive. Leander Meuris, Francis Santens and Nico Callewaert (VIB/UGent) have developed a technology that shortens the sugar structures whilst retaining the therapeutic efficiency. This technology has the potential to make the production of biotech medicines significantly simpler and cheaper.

Sugar structures are essential for the mechanism of biotech medicines

Nearly all biotech medicines are proteins. Most of these medicines contain a mixture of complicated sugar structures that are attached to the protein. These sugars are important for the mechanism of the medicine on the one hand, but on the other hand their complicated structure also causes problems during production. This makes the process expensive and often results in a mixture of the same protein with different sugars attached. In some cases, only a few of the many sugar forms are ideal for the treatment and others are not, meaning that a part of the production and treatment efficiency is lost.

Optimizing production cells

The proteins that are used as biotech medicines are produced by living cells. Leander Meuris and Nico Callewaert have altered these production cells so that they truncate the sugar structures to a smaller shape. In order to achieve this they added an enzyme obtained from a fungus, which truncates complex sugars, to the production cells. The stump that remains after truncation is then expanded by the cells to form two similar structures that are very suitable for therapeutic applications. Surprisingly, these production cells do not mind: they grow perfectly and continue to produce the therapeutic proteins.

A satisfying discovery

Nico Callewaert (VIB/UGent): "This technology has allowed us to solve an old biotech problem. Since the 1990s, nearly everyone has been working to make the sugar synthesis in biotech production cells as similar to human cells as possible. This is a very difficult task, because there are so many steps in this synthesis pathway. We have been able to create a 'detour' in this synthesis pathway in a fairly simple manner, making the pathway much shorter and simpler."

Leander Meuris (VIB/UGent): "You can compare it to a pollard willow. The branches of willows are pruned to keep the tree more functional, just like our technology in which we removed the complex branches to make biotech medicines more manageable and in some cases more efficient."


Story Source:

The above story is based on materials provided by VIB. Note: Materials may be edited for content and length.


Journal Reference:

  1. Leander Meuris, Francis Santens, Greg Elson, Nele Festjens, Morgane Boone, Anaλlle Dos Santos, Simon Devos, Franηois Rousseau, Evelyn Plets, Erica Houthuys, Pauline Malinge, Giovanni Magistrelli, Laura Cons, Laurence Chatel, Bart Devreese, Nico Callewaert. GlycoDelete engineering of mammalian cells simplifies N-glycosylation of recombinant proteins. Nature Biotechnology, 2014; 32 (5): 485 DOI: 10.1038/nbt.2885

Cite This Page:

VIB. "New technology simplifies production of biotech medicines." ScienceDaily. ScienceDaily, 14 May 2014. <www.sciencedaily.com/releases/2014/05/140514084507.htm>.
VIB. (2014, May 14). New technology simplifies production of biotech medicines. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/05/140514084507.htm
VIB. "New technology simplifies production of biotech medicines." ScienceDaily. www.sciencedaily.com/releases/2014/05/140514084507.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins